High materiality8/10
UBS target for Ascendis Pharma (ASND) up to $345
Why it may matterVerify against the original reporting
Significant upside implied by the high target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS sets/raises Ascendis target to $345; current price is $247.91.
- Target: $345
- Price: $247.91
- Analyst: UBS
Key facts
- 01
Target: $345
- 02
Posted price: $247.91
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.